Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc.

EWTX·NASDAQ

$36.21

-1.7%
HealthcareBiotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$3.90B
EPS-1.6300
P/E Ratio-22.21
Earnings Date08/06/2026

ewtx

Other Current Liabilities

Last Annual Value

20.35M

3-Year CAGR

72%

5-Year CAGR

114%

10-Year CAGR

51%

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. Competitors Analysis of Other Current Liabilities

EWTX · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
20.35M
52.9%48.7%N/A 
QURE logo
uniQure N.V.
NASDAQ:QURE
53.89M
5.5%79.7%48.0%
31.01M
86.0%141.6%N/A
46.54M
120.8%88.7%N/A
61.26M
68.7%74.8%48.5%
65.15M
146.5%60.2%N/A
48.26M
129.6%98.8%6.2%
13.04M
58.1%40.6%N/A
25.86M
N/AN/AN/A
Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. Fair Value Envelope

EWTX · NASDAQ

Our analysis suggests that EWTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $36.21, this represents a potential HIDDEN relative to our calculated worth for Edgewise Therapeutics, Inc..

Intrinsic Value
Current Price: $36.21